Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 4/20 | 0.66 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.66 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | P4HB | P07237 | 1/20 | 0.66 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.66 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.66 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285775 | 1.00 | MAPT (0.74) | MAPTTDP1NR4A1MEN1KMT2A | |
| SCHEMBL677473 | 0.93 | MAPT (0.63) | MAPTTDP1NR4A1MEN1KMT2A | |
| SCHEMBL15300175 | 0.87 | MAPT (0.78) | MAPTTDP1NR4A1MEN1KMT2A | |
| SCHEMBL23949811 | 0.86 | MAPT (0.81) | MAPTTDP1NR4A1MEN1KMT2A | |
| SCHEMBL681674 | 0.86 | MAPT (0.81) | MAPTTDP1NR4A1MEN1KMT2A | |
| SCHEMBL23949922 | 0.85 | NR4A1 (0.72) | MAPTTDP1NR4A1MEN1KMT2A | |
| SCHEMBL15321272 | 0.84 | MAPT (0.77) | MAPTTDP1NR4A1MEN1KMT2A | |
| SCHEMBL15321544 | 0.84 | MAPT (0.77) | MAPTTDP1NR4A1MEN1KMT2A | |
| SCHEMBL15300248 | 0.83 | MAPT (0.75) | MAPTTDP1MEN1KMT2AKDM4E | |
| SCHEMBL686171 | 0.82 | AR (0.84) | MAPTTDP1NR4A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| EP-2166841-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | Mission Pharmacal Company (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | MAPT 4872/4885TDP1 3880/4885NR4A1 4838/4885 |
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | MAPT 2660/4885TDP1 4075/4885NR4A1 3007/4885 |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | MAPT 4872/4885TDP1 3880/4885NR4A1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.